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Objective: to verify whether the review criteria for automated blood counts suggested by
the International Consensus Group for Hematology Review of the International Society for
Laboratory Hematology are suitable for the Hematology Laboratory of Hospital de Clinicas,
Universidade Federal do Paraná.
Methods: initially, the review criteria of the International Society for Laboratory Hematology
were adapted due to limitations in the Institution’s electronic hospital records and inter-
facing systems. The adapted review criteria were tested using 1977 samples. After this ﬁrst
assessment, an additional 180 inpatient samples were analyzed to evaluate the screening
criteria of the review criteria in conjunction with positive smear ﬁndings established by
the institution. The performance of the review criteria was veriﬁed by determining false
positive, false negative, true positive and true negative rates, sensitivity, speciﬁcity, positive
predictive value, negative predictive value, microscopic review rate and efﬁciency.
Results: initial analysis showed false negatives =6.73%, false positives = 23.27%, microscopic
review rate=46.03% and efﬁciency=70.0%. An evaluation of the screening criteria adapted
from the review criteria together with the positive smear ﬁndings of the institution showed
false negatives =15.5%, false positives = 10.5%, microscopic review rate=37.3% and efﬁ-
ciency=73.8%. In both situations the safety limit (false negative <5%) recommended by the
review criteria was exceeded.
Conclusions: the review criteria adapted from the International Society for Laboratory Hema-
tology are neither suitable nor safe for use in the hematology laboratory of the Hospital de
Clinicas. This implies a need to develop and validate institution-speciﬁc review criteria in
order to decrease false negative results to an acceptable and safe rate for patients.© 2014 Associac¸ão Bra
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Introduction
In 2005, the International Society for Laboratory Hematology
(ISLH) through the International Consensus Group for Hema-
tology Reviews, founded by hematologist Berend Houwen,
published a set of 41 rules applicable as criteria for the review
of automated complete blood counts (CBCs) and leukocyte
differential results of automated hematology analyzers, i.e.,
review criteria for automated complete blood counts (RC).1
These guidelines were formulated with the aims of reducing
costs and the turnaround time of the results without sacri-
ﬁcing their quality, and justifying the performance and skills
of the multiparametric hematology analyzers.2–4 Since then,
the rules suggested by the ISLH2 have been considered the
international standard to indicate situations requiring a blood
smear review (BSR). They take into account the age and gen-
der of patients, whether the request for CBC is the initial or a
subsequent one to monitor CBCs, or whether there are signif-
icant differences between the current results, and previously
validated and released results.2,4 In practice, they are based
on the set of screening thresholds for the results given by the
analyzers and in the presence or absence of suspect ﬂags. The
aim is to distinguish samples with a high probability of con-
taining relevant morphological alterations for the diagnosis
and treatment of patients. When the CBC results do not meet
the screening criteria, there are recommended procedures to
follow, speciﬁcally to prepare an adequate peripheral blood
smear for microscopic analysis.2
Hospital de Clínicas of the Universidade Federal do Paraná
(HC-UFPR) is a general Class IV hospital according to the
hospital classiﬁcation system of Brazil’s publically funded
healthcare system (SUS); it is the largest provider of gov-
ernment healthcare services in the State of Paraná with 510
beds. Moderately to highly complex procedures are carried
out in 59 departments. Approximately 61,000 consultations
are made per month. The clinical hematology laboratory is
located in the Diagnosis Support Service and contains two
types of hematology analyzers: the Sysmex XE-2100D and XT-
2000i (Sysmex Corporation, Kobe, Japan). Approximately 500
samples are sent for CBCs daily. Prior to the development of
the RC, 100%of CBCswere analyzedmicroscopically,which led
to delays in the release of the results even when performed by
experienced professionals.
According to Bain5 because BSRs and manual differential
leukocyte counts (MDLCs) are laborious and expensive, they
should be based on the RC. Thus, all hematology laborato-
ries must be encouraged to establish locally valid protocols
indicating when a BSR and MDLC should be performed. The
guidelines suggested by the ISLH can be the starting point as
long as they are interpreted in consideration of the experi-
ence of the laboratory staff, sophistication of the hematology
analyzers and the laboratory’s electronic records system, and
incidences of abnormalities and variations in reference values
of the population being tested.6,7 Thus, this study evaluated
the implementation of the RC suggested by the ISLH in theHC-
UFPRHematology Laboratory in order to determine automated
thresholds such thatmicroscopic analyses are performed only
under special circumstances. In addition, the study aimed
to deﬁne whether such guidelines could be tailored to the2014;36(3):219–225
population served or whether there is a need to establish and
evaluate speciﬁc RC for this Institution.
Methods
Study site and sample preparation
The investigation was conducted in the Hematology Labora-
tory of HC-UFPR after approval by the local Ethics Committee.
The samples were obtained in two stages. First, for ﬁve con-
secutive days, all laboratory samples were collected after the
release of the results into the electronic hospital records
system. A total of 1977 whole-blood samples in ethylenedi-
aminetetraacetic acid (EDTA)-K2 (1.8mg/mL) were analyzed
within 3h of collection. Of these, 1573 and 404 were ana-
lyzed using the XE-2100D and XT-2000i hematology analyzers,
respectively. Furthermore, to evaluate the screening criteria
adapted from the ISLH together with positive smear ﬁndings
(PSFs) of the HC-UFPR, an additional 180 inpatient samples
were collected randomly and analyzed using the XT-2000i
device; these samples were more likely to have PSFs because
they also had abnormal CBC results. The PSFs elaborated
by the HC-UFPR were intended to ensure clinically signiﬁ-
cant abnormalities were not omitted from the results, thereby
establishing a minimum threshold of information that should
be reported in the CBC results according to local consensus. All
numerical data and information from suspect ﬂags and blood
smear ﬁndings were recorded. Approximately 70% of the sam-
ples testedwere fromoutpatients,many ofwhomwere having
their ﬁrst blood count. The other 30% were from inpatients
from various hospital units (e.g., hematology, chemotherapy,
infectious diseases, intensive care units, emergency care),
many of whom had their blood counts monitored daily.
Adaptation of the review criteria of the International
Society for Laboratory Hematology according to local
requirements
In order to determine whether the performance of these RC
met local requirements or indicated the need to develop spe-
ciﬁc RC, the screening criteria and PSFs suggested by the
ISLH were initially evaluated. However, changes were made
to tailor the ISLH screening criteria to the hematology ana-
lyzers used in this study and particularly to adapt them to
the electronic hospital records system. The main adapta-
tions were associated with Delta Check rules, which were not
possible to implement because of limitations of the institu-
tion’s electronic hospital records and interfacing systems. The
adapted ISLH screening criteria concerning the possibility of
local implementation are shown in Table 1. Table 2 shows the
PSFs recommended by the ISLH.2 PSFs that differ from those
recommended by the ISLH were also created for the HC-UFPR
(Table 3) in an attempt to meet local requirements.
Sample classiﬁcation criteriaThe criteria followed to select samples for review were com-
pared with the ﬁndings of the peripheral BSR. A sample was
classiﬁed as true positive (TP) if it was positive for a particular
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Table 1 – Adapted International Society of Laboratory Hematology review criteria for automated complete blood counts.
Criterion or
rule
Parameter Adapted ISLH criteria Action proposed
1 WBC <4.0×103/L or >30.0×103/L BSR – conﬁrm leukopenia or leukocytosis by
blood smear estimate
2 Neutrophils# <1.0×103/L or >20.0×103/L BSR and if necessary MDLC
3 Lymphocytes# >5.0×103/L (adults) and >7.0×103/L (children
aged ≤12 years)
4 Monocytes# >1.5×103/L (adults) and >3.0×103/L (children
aged ≤12 years)
5 Eosinophils# >2.0×103/L
6 Basophils# >0.5×103/L
7 Hemoglobin <7.0 g/dL or >18.5 g/dL BSR – check RBC morphology
8 MCV <75 fL
or >105 fL
BSR – check microcytosis and macrocytosis
9 MCHC <30g/dL BSR – check hypochromia, verify time passed
after sample collection
10 MCHC >36.5 g/dL BSR – check lipemia, hemolysis,
hyperleukocytosis, RBC agglutination, and blood:
anticoagulant relation and presence of
spherocytes
11 RDW-CV >22.0% BSR – check anisocytosis
12 Reticulocytes >100×103/L BSR – check polychromatophilia
13 Platelets <100×103/L or >1000×103/L BSR – estimate platelet count on blood smear to
conﬁrm thrombocytopenia or thrombocytosis
14 MPV <5.0 fL or ≥12.5 fL BSR – check platelet size and morphology
15
Suspect ﬂags
Immature Granulocytes?; Immature
Granulocytes present
(Promyelocytes, myelocytes, and
metamyelocytes)
BSR and if necessary MDLC
Left shift?
Atypical lymphocytes?
Abnormal Lymphocytes/blasts?; Blasts?
(Myeloblasts, lymphoblasts, or atypical
lymphocytes)
Nucleated RBC? BSR and if positive, count erythroblasts/100
leukocytes. If >10%, correct total leukocyte count
Fragments?
(Schistocytes)
BSR – check presence of schistocytes
Dimorphic RBC population
(Erythrocyte population heterogeneous in size)
Check RBC histogram, observe RDW value and
verify anisocytosis on blood smear
RBC lyse resistance Rerun sample. If positive, BSR and check for
nucleated RBC and abnormal RBC morphology
Platelet clumps (generated by scattergram)? and
Platelet clumps (generated by the impedance
channel)?
Platelet clumps (generated by scattergram)?:
verify at the bottom of the scatter plot
Platelet clumps (generated by the impedance
channel)?: check platelet histogram. There is a
possibility of error in counting by impedance
Search for clots in the sample and platelet
aggregates on blood smear
Turbidity/Hemoglobin interference?;
Hemoglobin defect?
(Spurious hemoglobin measurement)
Check lipemia in sample. If the sample is
lipemic, remove the plasma and replace it with
the same volume of analyzer diluents. Rerun
only considering hemoglobin and recalculate red
blood cell indices
16 ALL If newborn Perform BSR and MDLC
17 (*) and (----) These symbols beside the counts on the readout
indicate that automated counts are not reliable
or not available for the sample in question,
respectively
MCV: mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; RDW-CV: red blood cell distribution width coefﬁcient of
variation; RBC: red blood cells; WBC: white blood cells; BSR: blood smear review; MDLC: manual differential leukocyte count.
# refers to absolute leukocyte counts
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Table 2 – Criteria for a positive smear recommended by
the International Society of Laboratory Hematology.
Morphology
RBC
2+/moderate or greater. The only exception is malaria, where
any ﬁnding will be considered a positive ﬁnding
Platelets
Giant platelets at either 2+/moderate or greater
Platelet clumps at > rare or occasional
WBC
Döhle bodies at either 2+/moderate or greater
Toxic granulation at either 2+/moderate or greater
Vacuoles at either 2+/moderate or greater
Abnormal cell types
Blasts≥1%
Myelocytes/promyelocytes≥1%
Metamyelocytes > 2%
Atypical lymphocytes > 5%
Nucleated RBC≥1%
Plasma cells≥1%
The International Society of Laboratory Hematology recommends
that theuseof bandcell counts and left shift suspect ﬂag (Left Shift?)
should be in accordance to laboratory standard operating proce-
dures. Thus, the Left Shift? Suspect ﬂag was used as a screening
criterion in this study and the band count was considered a posi-
tive smear ﬁnding when it was>8%.
Table 3 – Criteria for a positive smear recommended by
the Hospital de Clínicas da Universidade Federal do
Paraná.
Red blood cells
Anisocyto-
sis≥2+
Microcytes≥2+ Macrocytes≥2+
Poikilocyto-
sis≥2+
Elliptocytes≥3+ Stomatocytes≥3+
Codocytes≥2+ Dacryocytes≥2+ Schistocytes≥1+
Acantho-
cytes≥2+
Drepanocytes:
present
Spherocytes≥1+
Howell–Jolly:
present
Cabot ring: present Basophilic
stippling≥1+
Rouleaux≥1+ Hypochromia≥2+ Polychromatophilia≥2+
RBC
agglutination:
present
Hemoglobin C
crystals: present
Hematozoa: present
White blood cells
Döhle
bodies≥1+
Toxic
granulation≥1+
Cytoplasmic
vacuoles≥1+
Polylobo-
cytes≥1+
Hyposegmented
neutrophils:≥2+
Neutrophil
hypo/degranulation:
present
Auer rod:
present
Pseudo-Pelger-Huët:
present
Dysplastic cells:
present
Platelets
Giant
platelets≥1+
Microplatelets≥2+ Platelet aggregates:
present
Platelet aniso-
cytosis≥3+
Degranulated
platelets: present
Gray platelets:
present
Abnormal cell types
Blasts≥1% Promyelocytes≥1% Myelocytes≥1%
Metamyelo-
cytes≥2%
Bands>8% NRBC≥1/100
leukocytes
Plasma
cells≥1%
Prolymphocytes≥1% Atypical
lymphocytes≥5%
Source: adapted from Barnes et al.,2 Gulati et al.,3 and Hyun et al.10RBC: red blood cells; WBC: white blood cells; SOP: standard operat-
ing procedure.
screening criterion (Table 1) and the microscopic analysis pro-
duced some PSF (Tables 2 and 3). Meanwhile, a sample was
classiﬁed as false positive (FP) if it was positive for a particular
screening criterion with no PSF in the microscopic analysis.
A sample was classiﬁed as false negative (FN) if it was neg-
ative for all screening criteria and contained some PSF in
microscopic analysis. Finally, a sample was classiﬁed as true
negative (TN) if it was negative for all screening criteria and
the BSR did not show any PSFs.2,8
Considerations
Good laboratory practices and procedures for quality assur-
ance and quality control in hematology were followed to
ensure good performance. All settings and conﬁgurations of
the hematology analyzers followed the manufacturers’ rec-
ommendations. For all samples, the BSR and MDLC were
performed according to an adapted version of the H20-A2
Clinical and Laboratory Standards Institute (CSLI),9 because
each BSR and each MDLC was carried out by a single observer.
In most cases, 100 leukocytes were counted. In some cases
with leukocyte counts <0.03×103/L, leukocytes were not
observed and only a BSR could be performed. In other cases
with leukocyte counts above 50.0×103/L, the MDLC reached
200 leukocytes. Furthermore, in all samples, the BSR was per-
formed to identify any qualitative or quantitative changes in
red and white blood cells as well as platelets. Guidelines were
formulated to standardize the quantiﬁcation of morphologic
alterations and which terms are used to report changes in CBC
results. These guidelines were codiﬁed as standard operating
procedures (SOP).RBC: red blood cells; NRBC: nucleated red blood cells.
Statistical analysis
The sensitivity, speciﬁcity, positive predictive value, negative
predictive value, microscopic review rate, and efﬁciency of the
RC adapted from the ISLH were calculated as follows: sensitiv-
ity (%) =TP/(TP+FN)×100; speciﬁcity (%) =TN/(TN+FP)×100;
positive predictive value (%) =TP/(TP+FP)×100; negative
predictive value (%) =TN/(TN+FN)×100; microscopic review
rate (%) = (TP+FP)/(TP+FP+FN+TN)×100; and efﬁciency
(%) = (TP+TN)/(TP+FP+FN+TN)×100.8
Results
Out of the 1977 samples used in the initial investigation of
the adapted RC, 583 (29.49%) were positive and 1394 (70.51%)
were negative for relevant microscopic results, i.e., for PSFs.
Most samples failed to meet some screening criteria; usually
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Table 4 – Truth table of the adapted International Society
of Laboratory Hematology criteria.
Parameters (%) XE-2100D
(n=1573)
XT-2000i
(n=404)
Total
(n=1977)
True positive 21.93 25.99 22.76
False positive 21.93 28.46 23.27
True negative 48.77 41.34 47.24
False negative 7.37 4.21 6.73
Speciﬁcity 68.97 59.22 67.00
Sensitivity 74.84 86.06 77.19
Positive predictive value 50.00 47.73 49.45
Negative predictive value 86.86 90.76 87.54
Efﬁciency 70.69 67.32 70.00
Microscopic review rate 43.86 54.45 46.03
Note: the adapted ISLH screening criteria were tested considering
the ISLH criteria for a positive smear as shown in Table 2.
Table 5 – Incidence of false negatives: the adapted
International Society of Laboratory Hematology criteria
considering the International Society of Laboratory
Hematology criteria for a positive smear.
False negatives n %
Left shift > 8% bands 114 5.76
RBC morphology≥2+ 13 0.65
Myelocytes/promyelocytic≥1% 13 0.65
Giant platelets≥2+ 1 0.05
Total 141a 6.73%=133
samples of
1977
RBC: Red blood cell.
a Some samples showed more than one positive smear ﬁnding.
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Table 6 – Truth table of the adapted International Society
of Laboratory Hematology criteria considering the
Hospital de Clínicas da Universidade Federal do Paraná
criteria for a positive smear.
Parameters (%) XT-2000i (n=180)
True positive 26.7
False positive 10.5
True negative 47.3
False negative 15.5
Speciﬁcity 81.7
Sensitivity 63.2
Positive predictive value 71.6
Negative predictive value 75.2
Efﬁciency 73.9
Microscopic review rate 37.2
Table 7 – Incidence of false negatives: the adapted
International Society of Laboratory Hematology
screening criteria considering the Hospital de Clínicas
da Universidade Federal do Paraná criteria for a positive
smear.
False negatives n %
Left shift > 8% bands 8 4.44
Atypical lymphocytes≥5% 1 0.55
RBC morphology 10 5.55
Toxic granulation≥1+ 6 3.33
Cytoplasmic vacuoles≥1+ 1 0.55
Giant platelets≥1+ 6 3.33
Platelet aggregates: present 6 3.33
Blasts≥1% 1 0.55
Total 39a 15.5%=28
samples in
180
not.
In this study, after the initial evaluation of the RC adaptedrom one to four criteria but up to 15. The results obtained for
he validation of the screening criteria tailored from the ISLH
riteria, considering the positive smear criteria in Table 2, are
hown in Table 4.
The microscopic review rate during the initial investigation
Table 4) was quite high (46.03%) compared to the 30% recom-
ended by the American College of Pathologists.11 The main
ules producing FP results in the initial assessment were as
ollows: leukocytes <4.0×103/L (16.7% of total FPs), platelets
100×103/L (13.3% of total FPs), and suspect ﬂags (30% of
otal FPs). In the initial assessment of the RC adapted from
he ISLH criteria, therewere 133 FN samples (Table 5) including
14 with nuclear shift to the left in >8% of bands, 13 myelo-
ytes/promylocytes≥1%, 13 alterations in red blood cells, and
ne alteration in platelets.
The evaluation results for the screening criteria adapted
rom the ISLH in conjunction with the PSFs of the HC-UFPR
re shown in Tables 6 and 7. From the 180 samples analyzed,
6 contained PSFs. Using PSFs speciﬁc for the HC-UFPR, which
ere tailored to meet the requirements of the authors’ Insti-
ution, caused the screening criteria adapted from the ISLH to
e incapable of ﬁltering samples with relevant morphological
lterations (FN=15.5%), including one casewith blasts present
rom a patient with acute leukemia.RBC: Red blood cell.
a Some samples showed more than one positive smear ﬁnding.
In both analyses, the percentage of FN results exceeded
the reliability threshold of 5% established by the ISLH, causing
cases with serious illnesses to be overlooked.
Discussion
Despite the extensive capabilities of the latest-generation
multiparametric hematology analyzers, microscopic review of
blood smears still plays an important role in hematology lab-
oratories. The use of RC, which would allow the release of
automated counts without a BSR, is neither a widespread nor
standardized procedure. In practice, many laboratories simply
adopt published criteria or alter some criteria without empir-
ical evidence.12
Establishing and assessing a speciﬁc RC for a particu-
lar laboratory means that the ISLH screening and positive
smear criteriamust ﬁrst be validated, especially because these
criteria are international standards. Considering the actual
demands and capabilities of each laboratory, this initial vali-
dation clariﬁes whether such criteria require optimization orfrom the ISLH, 6.73% and 23.27% of FN and FP results were
oter.
r
1. International Society for Laboratory Hematology [Internet].
Available from: www.islh.org [accessed on 22.01.14].224 rev bras hematol hem
veriﬁed, respectively. Moreover, the microscopic review rate
was 46.03% and efﬁciency was 70.0%. The microscopic review
rate with the XT-2000i analyzer (54.45%) was higher than that
with the XE-2100D (43.86%). This is because the former ana-
lyzer was used by staff members on duty, who only attend
inpatients and emergency patients, who evidently have CBC
results that differ substantially from those of outpatients.
Thenegativepredictive valuedetermined in the initial eval-
uation using the screening criteria and positive smear criteria
showed that in 87.54% of the times in which the screening
criteria adapted from ISLH did not indicate the need for BSR,
the sample analyzed really did not contain any PSFs. The
observed sensitivity was 77.19%, indicating that out of 583
samples, 450 with PSFs were correctly screened by apply-
ing the RC adapted from the ISLH. As mentioned above, the
percentage of microscopic reviews (46.03%) greatly exceeded
the 30% recommended by the American College of Patholo-
gists. The fact that 30% of the FP results were of samples
with suspect ﬂagswith a nonexistentmicroscopic counterpart
indicated that the hematology analyzers used were guilty of
over-ﬂagging, i.e., they gave more warnings than necessary. As
the sensitivity of the suspect ﬂags had been adjusted by tech-
nicians of the manufacturer, we suggest that each laboratory
should evaluate the efﬁciency of each suspect ﬂag from the
analyzers, therebymaking proper adjustments to the sensitiv-
ity of the hematology analyzer or deﬁning whether a suspect
ﬂag is actually useful as a screening criterion.
A total of 13.3% of samples had a platelet count
<100×103/L in the initial evaluation of the RC adapted from
the ISLH; this is relatively high considering the sampling was
representative of the local reality. Therefore, the microscope
estimate of the platelet count should always be performed
on samples with this proﬁle in order to verify how well it
complies with automated counting and to search for platelet
aggregates and giant platelets, which are factors that produce
underestimates.13
Moreover, the screening criteria adapted from the ISLH
were tested according to the PSFs of the HC-UFPR; 15.5% and
10.5% of FNs and FPs were veriﬁed, respectively. In addition,
the microscopic review rate was 37.3%, and the efﬁciency was
73.8%. One FN sample contained blasts. It is unacceptable to
fail to detect cases of undiagnosed hematological malignan-
cies; therefore, each institution should evaluate the need to
perform BSRs in all patients in the hematology unit even at
the expense of an increased microscopic review rate.
Despite some studies suggesting poor clinical practice
when counting bands,14–16 in this study, a band count>8%was
chosen as the positive smear criterion, particularly because
a substantial proportion of doctors in Brazil posit there are
associations of a nuclear shift to the left of neutrophils with
infectious and inﬂammatory conditions. The FN analysis in
the present study revealed a high occurrence of a nuclear shift
to the left > 8% bands. Nevertheless, the technical limitations
of MDLC must be taken into account when interpreting these
results, especially results regarding band counts and varia-
tions occurring as a result of age, gender, and conditions such
15,17as pregnancy and physical exercise.
The greatest amendment made to the RC of the ISLH was
regarding the Delta check rules. These rules recognize mor-
phological abnormalities detected and validated in previous2014;36(3):219–225
analyses as well as discrepancies between the results of the
current analysis and previous results from up to ﬁve days ear-
lier. The Delta check limit threshold for a particular parameter
is the amount by which a result can differ from a previous
one; this difference can be expressed as the percentage dif-
ference or the absolute value in the unit of the hematological
parameter in question. Delta limits should be established by
each laboratory taking into account the physiopathological
aspects and technical characteristics of the hematology ana-
lyzers used.
Although the Delta check rules play important roles in the
efﬁciency and reliability of the CBC results directly released
without a BSR, many clinical laboratories are incapable of
implementing them in their electronic records or interfacing
systems because of high software development costs. Even in
developed countries, some laboratories are still incapable of
modifying their electronic record systems to incorporate such
regulations.18
Another equally important factor is how unfamiliar labo-
ratory professionals are with these rules, which make their
dissemination and implementation difﬁcult. The ISLH does
not suggest speciﬁc Delta check limits, leaving them to the
discretion of the laboratory. This could lead to small differ-
ences in the efﬁciency of the ISLH criteria when applied by
different laboratories using different Delta limits since the
International Consensus Group for Hematology Reviews only
suggests speciﬁc actions for situations in which the Delta lim-
its individually established by the laboratories are exceeded.
Conclusions
Neither assessment carried out in this study proved to be
reliable, because the FN rates exceeded 5%. Moreover, the
microscopic review rates were high, which may pose prob-
lems when attempting to decrease the turnaround time of
results and when laboratories have an insufﬁcient number
of experienced professionals to perform the BSR. Therefore,
in conclusion, new criteria should be developed and evalu-
ated taking into account local peculiarities, requirements, and
opportunitieswhile aiming not to overlook sampleswith PSFs.
To this end, additional studies are being carried out by the
authors with the aim of developing a method to help establish
and evaluate the efﬁciency of criteria for reviewing automated
CBC results.
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